Original Source(s)
Related Content
Can LAI-CAB Sustain Long-Term PrEP Use?
A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.
July 17, 2026
-
4 min
FDA Approves Gedatolisib in Breast Cancer
In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.
July 14, 2026
-
2 min
May Lower RFR Signal Repeat Revascularization?
Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.
July 28, 2026
-
4 min
